BIIB - Biogen Inc.

Biogen is a global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative therapies for individuals with serious and complex diseases around the world. Their drug portfolio includes treatments for multiple sclerosis (MS), spinal muscular atrophy (SMA), and rare neurological diseases such as amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia. They have also made strides in addressing Alzheimer's disease through their collaborations, such as with Eisai for the commercialization of the anti-amyloid antibody LEQEMBI (lecanemab). Biogen's business model leveraging internal R&D along with strategic partnerships enables them to advance their treatment pipeline, which is heavily focused on neurology and specialized immunology.